Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy

CompletedOBSERVATIONAL
Enrollment

1,025

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

January 22, 2024

Study Completion Date

January 22, 2024

Conditions
Adnexal MassOvarian CancerPelvic Mass
Trial Locations (26)

1605

The Medical City, Pasig

3052

Royal Women's Hospital, Parkville

31404

Memorial Health University Medical Center, Savannah

32224

Mayo Clinic, Jacksonville

33612

University of South Florida USF Health, OB/Gyn, Tampa

60521

Dr. Sudarshan K. Sharma, Ltd. - Gynecologic Oncology, Hinsdale

68114

Nebraska Methodist Hospital, Omaha

77030

Houston Methodist, Houston

87109

Optimum Clinical Research Group - Southwest Women's Oncology & Health, Albuquerque

90033

University of Southern California, Los Angeles

94086

Palo Alto Medical Foundation, Sunnyvale

95128

Bay Area Gynecology Oncology, San Jose

Unknown

Hospital Sultan Ismail, Johor Bahru

Hospital Raja Perempuan Zainab II, Kota Bharu

Hospital Ampang, Ampang

Hospital Tengku Ampuan Afzan, Kuantan

Hospital Raja Permaisuri Bainun, Ipoh

Hospital Taiping, Taiping

Hospital Seberang Jaya, Seberang Jaya

Hospital Wanita Dan Kanak-kanak Sabah, Kota Kinabalu

Hospital Umum Sarawak, Kuching

Hospital Miri, Miri

Hospital Sibu, Sibu

Hospital Selayang, Batu Caves

National Kidney and Transplant Institute, Quezon City

Philippine General Hospital, Manila

All Listed Sponsors
lead

Venn Biosciences Corporation

INDUSTRY

NCT03837327 - Clinical Validation of the InterVenn Ovarian CAncer Liquid Biopsy | Biotech Hunter | Biotech Hunter